| 李 婷,郑宝林,叶美杏,黄艳华,陈君立,梁建亮.通痹胶囊治疗类风湿关节炎的疗效及对微循环和血清MMP-1、MMP-3的影响[J].,2020,(16):3117-3120 |
| 通痹胶囊治疗类风湿关节炎的疗效及对微循环和血清MMP-1、MMP-3的影响 |
| The Therapeutic Effect of Tongbi Capsule on Rheumatoid Arthritis and Its Effect on Microcirculation and Serum MMP-1 and MMP-3 |
| 投稿时间：2020-02-06 修订日期：2020-02-28 |
| DOI：10.13241/j.cnki.pmb.2020.16.025 |
| 中文关键词: 通痹胶囊 类风湿关节炎 疗效 微循环 基质金属蛋白酶-1 基质金属蛋白酶-3 |
| 英文关键词: Tongbi capsule Rheumatoid arthritis Efficacy Microcirculation Matrix metalloproteinase-1 Matrix metalloproteinase-3 |
| 基金项目:2018年度广东省中医药局科研项目（20181250） |
|
| 摘要点击次数: 713 |
| 全文下载次数: 443 |
| 中文摘要: |
| 摘要 目的：探讨通痹胶囊治疗类风湿关节炎（RA）的疗效及对微循环指标和基质金属蛋白酶-1（MMP-1）、血清基质金属蛋白酶-3（MMP-3）的影响。方法：选取2016年1月~2018年9月期间我院收治的90例RA患者，按照随机数字表法分为研究组（n=45）、对照组（n=45）。对照组患者给予来氟米特、甲氨蝶呤常规治疗，研究组在对照组基础上联合通痹胶囊治疗，比较两组患者疗效、治疗前后的微循环指标[血管阻力指数（RI）、舒张期峰值速度（EDV）以及收缩期峰值速度（PSV）]、MMP-1、MMP-3、类风湿因子滴度（RF）、C反应蛋白（CRP）、红细胞沉降率（ESR）、抗链球菌溶血素"O"（ASO），记录两组治疗期间不良反应发生情况。结果：研究组治疗4个月后的临床总有效率高于对照组（P<0.05）。两组患者治疗4个月后RI、MMP-1、MMP-3、CRP、RF、ESR、ASO下降，且研究组低于对照组（P<0.05）；EDV、PSV升高，且研究组高于对照组（P<0.05）。两组患者不良反应发生率比较无差异（P>0.05）。结论：在常规治疗的基础上联合通痹胶囊可有效缓解RA病情，改善机体微循环，降低血清MMP-3、MMP-1水平，且用药安全性较好。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the therapeutic effect of Tongbi capsule on rheumatoid arthritis (RA) and its influence on microcirculation index, matrix metalloproteinase-1 (MMP-1) and serum matrix metalloproteinase-3 (MMP-3). Methods: 90 patients with RA admitted to our hospital from January 2016 to September 2018 were selected, they were divided into study group (n=45), control group (n=45) according to the random number table method. The control group was treated with leflunomide and methotrexate. The study group was treated with Tongbi capsule on the basis of the control group. The therapeutic effect, microcirculation indexes before and after treatment [Vascular resistance index (RI), diastolic peak velocity (EDV) and systolic peak velocity (PSV)], MMP-1, MMP-3, Rheumatoid factor titer (RF), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), antistreptolysin "O" (ASO) of the two groups were compared, adverse reactions were recorded. Results: The total clinical effective rate of the study group was higher than that of the control group (P<0.05). The RI, MMP-1, MMP-3, CRP, RF, ESR and ASO of the two groups decreased after 4 months of treatment, and the study group was lower than the control group (P<0.05); EDV and PSV increased, and the study group was higher than the control group (P<0.05). There was no difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: on the basis of routine treatment, Tongbi capsule can effectively alleviate RA, improve microcirculation, reduce the levels of MMP-3 and MMP-1 in serum, and the drug safety is good. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
